<DOC>
	<DOC>NCT02500407</DOC>
	<brief_summary>This study is designed to evaluate the safety and pharmacokinetics of BTCT4465A when administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.</brief_summary>
	<brief_title>A Safety and Pharmacokinetic Study of BTCT4465A, With or Without Single-dose Obinutuzumab Pretreatment, in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy at least 12 weeks Doseescalation stage: Grade 1 to 3b follicular lymphoma (FL), marginal zone lymphoma (MZL), transformed FL, Richter's transformation, diffuse large Bcell lymphoma (DLBCL), primary mediastinal Bcell lymphoma (PMBCL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), or CLL Doseexpansion stage: DLBCL, transformed FL, Grade 1 to 3a FL, MZL, or CLL Adverse events from prior anticancer therapy resolved to Grade 1 or better Adequate hepatic, hematologic, and renal function For participants and partners of childbearing potential, agreement to remain abstinent or utilize effective contraception Pregnant or lactating women Monoclonal antibody, radioimmunoconjugate, antibodydrug conjugate, radiotherapy, chemotherapy, or other investigational anticancer agent within 4 weeks prior to study drug Systemic immunotherapy within 12 weeks or 5 halflives of drug prior to study drug Systemic immunosuppressive medication within 2 weeks prior to study drug Autologous stem cell transplantation (SCT) within 100 days prior to study drug, or any prior allogeneic SCT or solid organ transplantation Autoimmune disease with the exception of controlled/treated hypothyroidism, diseaserelated immune thrombocytopenic purpura, or hemolytic anemia History of confirmed progressive multifocal leukoencephalopathy (PML) History of central nervous system (CNS) lymphoma or other CNS disease Significant cardiovascular or pulmonary disease Current infection, or prior infection requiring IV antibiotics and/or hospitalization within 4 weeks prior to study drug Major surgery within 4 weeks prior to study drug Hepatitis B or C or human immunodeficiency virus (HIV) Receipt of a live attenuated vaccine within 4 weeks prior to study drug History of drug or alcohol abuse within 12 weeks prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>